Apremilast Promising in Phase III for PsA

Apremilast Promising in Phase III for PsA

Treatment of psoriatic arthritis with the oral phosphodiesterase 4 inhibitor apremilast was effective for both the articular and cutaneous manifestations of the disease. Note that the most common adverse events observed during the placebo-controlled

(Visited 1 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.